Personalis Inc

Personalis, Inc. engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Personalis Inc excels in Q4 earnings, eyes growth through strategic focus

Personalis Inc's Q4 2022 earnings call highlighted strong financial performance, strategic focus on MRD, and guidance for 2023 amidst market challenges and opportunities.
The company's strengths in partnerships, product innovation, and financial management position it well for future growth and success in a competitive landscape.
While facing challenges in sample delivery, margin expectations, and operational changes, Personalis Inc is poised to leverage opportunities in partnerships, product launches, and market expansion.
Navigating the evolving landscape with resilience and adaptability, Personalis Inc aims to drive growth, profitability, and innovation in the coming year.

Personalis Inc reports strong Q1 revenue growth and oncology progress

Personalis Inc's Q1 2023 performance showcased revenue growth and progress in oncology.
The company aims to launch NeXT Personal for clinical use by Q4 2023, targeting cancer diagnostics.
Challenges include managing expenses, net loss, and ensuring efficient cash usage for financial goals.

Personalis Inc reports Q2 revenue growth, eyes strong collaborations

Personalis Inc is strategically positioned for growth in oncology with NeXT Personal and key collaborations, despite facing financial challenges and revenue fluctuations.
The company's strong balance sheet and prudent expense management offer financial stability and a 2-year cash runway, supporting future growth opportunities.
Legal battles and variability in data publication speed present challenges, but active engagement in scientific advancement and partnerships drive credibility and revenue potential.
Overall, Personalis is navigating a complex landscape with a focus on innovation, financial sustainability, and scientific credibility to drive future success.

Personalis Inc reports strong Q3 growth and strategic partnerships

Personalis Inc's Q3 performance reflects growth in key revenue segments and strategic advancements in cancer research collaborations and product launches.
While facing challenges in net losses and reimbursement coverage, the company's focus on partnerships, operational efficiency, and revenue growth presents opportunities for market expansion.
With a strong cash position, reduced OpEx, and plans for revenue growth, Personalis Inc is poised for strategic growth and market capture in the genomics industry.

Personalis Inc (PSNL) reports robust Q4 performance and strategic growth plans

Personalis Inc (PSNL) delivered strong financial performance in Q4 2023, with revenue growth, improved margins, and cost efficiency measures.
The company's focus on strategic collaborations, strong financial position, and targeted market approach position it well for future growth.
Challenges in revenue guidance, regulatory hurdles, and managing partnerships require careful navigation, but opportunities in key cancer areas offer significant growth potential.

Personalis Inc surpasses revenue targets, eyes MRD test leadership

Personalis Inc demonstrated strong financial performance in Q1 2024, exceeding revenue guidance.
The company's focus on MRD testing and strong IP protections positions it well for future growth.
Challenges lie in balancing test adoption with reimbursement considerations for sustained growth.
Opportunities exist to solidify NeXT Personal's position in clinical diagnostics through strategic planning.

Personalis Inc reports robust Q2 earnings, eyes growth opportunities

Personalis Inc delivered strong financial performance in Q2 2024, driven by revenue growth and strategic initiatives.
The company's focus on MRD testing, partnerships, and innovative strategies position them for future growth.
While challenges like market competition and cash management exist, opportunities in diversification and partnerships are promising.

Personalis Inc reports robust Q3 revenue growth and strategic expansion

Personalis Inc's Q3 performance reflects strong revenue growth and financial stability, underpinned by a focus on innovation and market expansion.
While facing challenges in achieving reimbursement and managing expenses, the company's strategic initiatives position it well for future growth and profitability.
With a clear roadmap for revenue expansion and a commitment to financial efficiency, Personalis Inc is poised to capitalize on growth opportunities in the MRD testing market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced that the company has filed a second patent infringement suit against Foresight Diagnostics Inc. Personalis is seeking injunctive relief and monetary damages. This suit brings the total number of patents that Personalis alleges Foresight Diagnostics has infringed to seven. The additional suit, filed in the U.S. District Court for the District of Colorado, alleges that Foresight improperly based its solid tumor mini.

Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics

FREMONT, Calif.--(BUSINESS WIRE)--Dr. Kenneth J. Widder Joins Personalis Board of Directors.

Dr. Kenneth J. Widder Joins Personalis Board of Directors

FREMONT, Calif.--(BUSINESS WIRE)--Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023.

Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023

FREMONT, Calif. & KASHIWA, Japan & OSAKA, Japan--(BUSINESS WIRE)--Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer.

Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer

Personalis (PSNL) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.63 per share a year ago.

Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2023 and provided recent business highlights. Recent Business Updates Announced a collaboration with Cancer Research UK, University College London, and the Francis Crick Institute to utilize our ultra-sensitive NeXT Personal® tumor-informed liquid biopsy assay for the TRACERx study, a groundbreaking lung c.

Personalis Reports First Quarter 2023 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, ABRCC, and Criterium announce major prospective clinical trial.

Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2023 financial results on Wednesday, May 3, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Personalis to Announce First Quarter 2023 Financial Results

Today, we put diagnostic firm Personalis, Inc. back in the spotlight as the shares go for less than the company's net cash on the balance sheet. The company has brought in a new CEO and announced significant cost saving measures.

Personalis: Revisiting The Investment Thesis

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19 at 3:00 p.m. Eastern Time. About Personalis, Inc. At Personalis, we are transforming the active management of cancer through breakthrough personalized testing.

Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference

FREMONT, Calif. & LONDON--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), Cancer Research UK's Cancer Research Horizons, University College London (UCL), and the Francis Crick Institute today announced a collaboration to deploy NeXT Personal, a personalized liquid biopsy-based research assay, for the TRACERx study, a groundbreaking lung cancer initiative funded by Cancer Research UK.

Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes from April 14-19, 2023 in Orlando, Florida.

Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023

AstraZeneca

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it will continue its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN), a global science-led biopharmaceutical company, to explore ultra-sensitive molecular residual disease (MRD) measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.

Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Board of Directors has appointed Christopher Hall as Chief Executive Officer (CEO) and a member of the Board, effective immediately, in addition to his role as President. Hall will lead the Company's efforts to drive a new paradigm for the active management of cancer with the aim of guiding care from biopsy throughout the life of the patient.

Personalis Appoints Christopher Hall as Chief Executive Officer

Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Personalis (PSNL) Upgraded to Buy: Here's What You Should Know

Personalis, Inc. (NASDAQ:PSNL ) Q4 2022 Results Conference Call February 23, 2023 5:00 PM ET Company Participants Caroline Corner - Investor Relations Aaron Tachibana - Interim Chief Financial Officer and Chief Financial Officer Chris Hall - President Rich Chen - Chief Medical Officer, and SVP of R&D Conference Call Participants Joseph Flanagan - Cowen Vivian Bais - BTIG Arthur He - H.C. Wainwright Operator Good day, ladies and gentlemen, and welcome to the Personalis Fourth Quarter 2022 Earnings Conference Call.

Personalis, Inc. (PSNL) Q4 2022 Earnings Call Transcript

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business highlights.

Personalis Reports Fourth Quarter and Full Year 2022 Financial Results

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.

Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results

Ardelyx

Athenex

Use these tips for making money with penny stocks The post A Short Guide to Making Money With Penny Stocks in 2023  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

A Short Guide to Making Money With Penny Stocks in 2023

Moderna

FREMONT, Calif.--( BUSINESS WIRE )--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The platform, which was also utilized in the vaccine candidate's Phase 2b clinical study, will be used to sequence genomic information from a patient's tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials

Personalis is a small-cap cancer genomics company with a next-gen cancer diagnostics platform whose stock has lost over 80% of its value over the past twelve months. Personalis is reporting substantial losses, however, the company's strong balance sheet could provide them with enough runway to prove they are a legitimate player in a $30+B market.

Personalis: Looking For A Potential Turnaround In 2023

FREMONT, Calif.--( BUSINESS WIRE )--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2022.

Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

FREMONT, Calif.--( BUSINESS WIRE )--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West has served in the DNA sequencing field for over forty years, and co-founded Personalis with four Stanford professors in 2011.

Personalis Announces CEO Retirement and Transition

MENLO PARK, Calif. & SAN FRANCISCO--( BUSINESS WIRE )--Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal cancer. The research efforts will use Personalis' NeXT Personal™ assay to evaluate circulating tumor DNA (ctDNA)-based signatures associated with treatment response and adverse events in a cohort of late-stage colorectal cancer patients receiving capecitabine together with pembrolizumab and bevacizumab.

Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer

MENLO PARK, Calif.--( BUSINESS WIRE )--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 34th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 1:30 p.m. Eastern Time in New York, NY.

News for Personalis Inc Stock (PSNL)